Matinas BioPharma Reports $3.25 Million Net Loss, Seeks Funding Amid Strategic Changes

Matinas BioPharma Holdings, Inc. reported a net loss of $3.25 million for the six months ended June 30, 2026, a significant improvement compared to a net loss of $6.90 million during the same period in 2025. The company did not generate any revenue during the first half of 2026, consistent with the previous year. General and administrative expenses decreased to $3.49 million from $3.70 million, primarily due to reduced personnel costs and lower operating lease expenses following the termination of its Bridgewater facility lease. The company’s total assets decreased to $3.41 million as of June 30, 2026, down from $7.21 million at the end of 2025, largely due to a reduction in cash and cash equivalents.

In terms of operational changes, Matinas BioPharma has entered into a Business Combination Agreement with GH Power Inc. and a Stock Purchase Agreement with Azurity Pharmaceuticals, Inc. for the sale of its subsidiary, Matinas BioPharma Nanotechnologies, Inc. These strategic moves are expected to reshape the company’s focus, as the current business of GH Power is anticipated to become the primary business of the combined entity. The company has also received net proceeds of approximately $575,000 from a Series D Financing and $2.32 million from a Warrant Inducement, which are critical for its liquidity.

The company’s cash and cash equivalents stood at $761,000 as of June 30, 2026, a decline from $4.25 million at the end of 2025. This decline raises concerns about the company’s ability to fund its operations for the next twelve months, leading to substantial doubt about its ability to continue as a going concern. The company has indicated that it may need to secure additional funding to continue operations if the planned transactions do not close.

Matinas BioPharma's employee headcount has also been reduced, contributing to lower general and administrative expenses. The company did not incur any research and development expenses during the first half of 2026, a decrease from $85,000 in the same period of 2025, reflecting a pause in its clinical development activities. The company’s focus is now on completing the business combination and sale of its subsidiary, which it hopes will provide a more stable financial footing moving forward.

Looking ahead, Matinas BioPharma's management has expressed uncertainty regarding its future operations, contingent on the successful completion of the Business Combination and Stock Purchase Agreement. The company is actively seeking to raise additional capital and is exploring various funding options to ensure its operational viability. The outcome of these strategic initiatives will be crucial for the company’s future direction and financial health.